NCT01285089

Observational Study on the Use of NovoSeven® for Haemostatic Treatment of Bleeding Episodes in Patients With Acquired Haemophilia

Prospective French Study on ACQUIred Haemophilia Treatment With Recombinant Factor VIIa (NovoSeven®) A Prospective Observational Study on the Use of NovoSeven® (Activated Recombinant Human Factor VIIa) for the Haemostatic Treatment of Bleeding Episodes in Patients With Acquired Haemophilia

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 21 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

This study is conducted in Europe. The aim of this prospective, observational study are to describe the different clinical practice and detailed haemostatic management of activated recombinant human factor VII (NovoSeven®) in patients with acquired haemophilia in France. The secondary aim is to assess the primary haemostasis disorder associated with the coagulation disorders, if available.

Conditions

• Acquired Bleeding Disorder
• Acquired Haemophilia

Interventions

Type	Name	Description
DRUG	activated recombinant human factor VII	Data collection of the use of activated recombinant human factor VII observed through real-world treatment practices

Timeline

• Start date: 2010-12-01
• Primary completion: 2013-10-01
• Completion: 2013-10-01
• First posted: 2011-01-27
• Last updated: 2014-01-30

Locations

1 site across 1 country: France